STOCK TITAN

Century Therapeutics SVP sells 254 shares for taxes

Century Therapeutics SVP Finance & Operations sold shares automatically to cover taxes from RSU vesting, retaining over 500,000 shares.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Century Therapeutics, Inc. (IPSC) reported that Douglas Carr, its SVP Finance & Operations, had an automatic sale of 254 shares of common stock on September 8, 2026 at $2.05 per share. According to the footnote, the sale covered tax withholding obligations from vesting restricted stock units, was not discretionary, and left him holding 504,565 shares directly.

Positive

  • None.

Negative

  • None.
Insider Carr Douglas
Role SVP Finance & Operations
Sold 254 shs ($520.70)
Type Security Shares Price Value
Sale Common Stock F1 254 $2.05 $520.70
Holdings After Transaction: Common Stock — 504,565 shares (Direct)
Footnotes (1)
  1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Shares sold 254 shares Automatic sale on September 8, 2026 to cover tax withholding
Sale price per share $2.05 per share Common stock sale on September 8, 2026
Shares owned after transaction 504,565 shares Direct beneficial ownership by Douglas Carr after the sale
Net buy/sell shares 254 shares net sold One sale transaction; no purchases reported in this Form 4
restricted stock units financial
"in connection with the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"shares required to be sold ... to cover tax withholding obligations"
Form 4 regulatory
"The sales reported on this Form 4 represent the number of shares"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did IPSC report for Douglas Carr on this Form 4?

The filing reports that Douglas Carr, SVP Finance & Operations, sold 254 shares of Century Therapeutics common stock on September 8, 2026 at $2.05 per share in a single reported transaction.

Why did the IPSC insider sell 254 shares on September 8, 2026?

The sales were made to cover tax withholding obligations arising from the vesting of restricted stock units. The filing states these sales were automatic and not at Douglas Carr’s discretion.

How many IPSC shares does Douglas Carr hold after this Form 4 transaction?

After the reported sale, Douglas Carr beneficially owns 504,565 shares of Century Therapeutics common stock, held directly according to the Form 4 data.

Was the IPSC insider sale under a Rule 10b5-1 trading plan?

No. The Form 4’s Rule 10b5-1 checkbox is not checked, and the footnote explains the sale was automatic to cover taxes, not discretionary and not identified as made under a Rule 10b5-1 plan.

What price was received in the IPSC insider sale on September 8, 2026?

The 254 shares of Century Therapeutics common stock were sold at a price of $2.05 per share, as reported in the Form 4 transaction details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carr Douglas

(Last)(First)(Middle)
C/O CENTURY THERAPEUTICS, INC.
25 N 38TH STREET, 12TH FLOOR

(Street)
PHILADELPHIA PENNSYLVANIA 19104

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP Finance & Operations
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/08/2026S(1)254D$2.05504,565D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
/s/ Douglas Carr09/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading